| Literature DB >> 15863301 |
Jeffrey A Pfefferkorn1, Meredith L Greene, Richard A Nugent, Rebecca J Gross, Mark A Mitchell, Barry C Finzel, Melissa S Harris, Peter A Wells, John A Shelly, Robert A Anstadt, Robert E Kilkuskie, Laurice A Kopta, Francis J Schwende.
Abstract
A novel series of nonnucleoside HCV NS5B polymerase inhibitors were prepared from (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid, a high throughput screening lead. SAR studies combined with structure based drug design focusing on the southern heterobiaryl region of the template led to the synthesis of several potent and orally bioavailable lead compounds. X-ray crystallography studies were also performed to understand the interaction of these inhibitors with HCV NS5B polymerase.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15863301 DOI： 10.1016/j.bmcl.2005.03.066
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823